Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium tc99m mertiatide
- Development stage
- Approved
- Lead developer
- Mallinckrodt
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Technetium tc99m mertiatide is a radiopharmaceutical agent used in nuclear medicine primarily for dynamic renal imaging. After intravenous injection, it rapidly binds to plasma proteins and is excreted mainly via **active tubular secretion** with some contribution from glomerular filtration. The radiolabeled compound emits gamma rays detectable by gamma cameras, allowing assessment of renal perfusion, function, drainage, and detection of congenital or acquired kidney abnormalities, obstruction, or calculi in adults and children. The agent is widely used to indirectly evaluate effective renal plasma flow, particularly in patients with possible renovascular hypertension, chronic kidney disease, and post-renal transplantation surveillance.
- Brand names
- Technescan Mag3
- Other names
- technetium (99mTc) mertiatidetc-99m mertiatidetc99m mertiatidetc 99m mertiatidetechnetium-99m mertiatidetechnetium99m mertiatidetechnetium 99m mertiatide
02
Targets
ABCC2 (ATP-binding cassette sub-family C member 2)ABCC4 (Multidrug resistance-associated protein 4)OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)
Beyond the preview
Go deeper on technetium tc99m mertiatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium tc99m mertiatide.